Could skipping pills keep cancer at bay for less?
NCT ID NCT07077161
Summary
This study is testing a new way to take the kidney cancer drug cabozantinib. Researchers want to see if taking a higher dose for one or two days, then skipping a day, works as well as taking a smaller dose every single day. They are checking if this new schedule keeps enough medicine in the body to fight the cancer while possibly causing fewer side effects and lowering costs for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
LUMC
RECRUITINGLeiden, South Holland, 2333ZA, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.